Immunization with apical membrane antigen 1 confers sterile infection-blocking immunity against plasmodium sporozoite challenge in a rodent model

17Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

Abstract

Apical membrane antigen 1 (AMA-1) is a leading blood-stage malaria vaccine candidate. Consistent with a key role in erythrocytic invasion, AMA-1-specific antibodies have been implicated in AMA-1-induced protective immunity. AMA-1 is also expressed in sporozoites and in mature liver schizonts where it may be a target of protective cell-mediated immunity. Here, we demonstrate for the first time that immunization with AMA-1 can induce sterile infection-blocking immunity against Plasmodium sporozoite challenge in 80% of immunized mice. Significantly higher levels of gamma interferon (IFN-γ)/interleukin-2 (IL-2)/tumor necrosis factor (TNF) multifunctional T cells were noted in immunized mice than in control mice. We also report the first identification of minimal CD8+ and CD4+ T cell epitopes on Plasmodium yoelii AMA-1. These data establish AMA-1 as a target of both preerythrocytic- and erythrocytic-stage protective immune responses and validate vaccine approaches designed to induce both cellular and humoral immunity.

Cite

CITATION STYLE

APA

Schussek, S., Trieu, A., Apte, S. H., Sidney, J., Sette, A., & Doolana, D. L. (2013). Immunization with apical membrane antigen 1 confers sterile infection-blocking immunity against plasmodium sporozoite challenge in a rodent model. Infection and Immunity, 81(10), 3586–3599. https://doi.org/10.1128/IAI.00544-13

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free